Physician profile
Heidi Sami
NPI 1720305857
$7,722.41
in general payments reported to CMS, 2019-2025
30 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,308 · 2020: $359 · 2021: $509 · 2022: $298 · 2023: $720 · 2024: $428 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.28 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,711.40 | 2019-2023 | Krystexxa |
| Abbvie INC. | $844.63 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $601.52 | 2019-2025 | Tremfya |
| Amgen INC. | $592.44 | 2019-2025 | Evenity, Krystexxa, Tavneos |
| Lilly USA, LLC | $517.87 | 2019-2022 | |
| Ucb, INC. | $459.37 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $295.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $295.25 | 2019-2023 | Orencia |
| Mallinckrodt Enterprises LLC | $185.31 | 2019 | |
| Sobi, INC | $156.73 | 2019-2025 | |
| Celgene Corporation | $122.22 | 2019 | |
| Glaxosmithkline, LLC. | $108.04 | 2019-2025 | Benlysta |
| Radius Health, INC. | $105.16 | 2019-2020 | |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Pfizer INC. | $87.79 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.81 | 2023-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $75.93 | 2024-2025 | Sovuna, Purified Cortrophin Gel |
| Genentech USA, INC. | $59.40 | 2019-2024 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.38 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $49.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $41.61 | 2023 | Strensiq |
| Sandoz INC. | $33.75 | 2023-2025 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $30.59 | 2025 | Acthar |
| Boston Scientific Corporation | $27.78 | 2019 | |
| Mylan Institutional INC. | $23.96 | 2023 | Hulio |
| Aurinia Pharma U.S., INC. | $21.19 | 2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $18.92 | 2025 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $14.26 | 2020 | |
| Genzyme Corporation | $11.37 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Sami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.